MedTrace Logo

Dexmedetomidine for Attenuation of Pressor Response

NCT06592027 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-09-19

No results posted yet for this study

Summary

Direct laryngoscopy and tracheal intubation are usually associated by hemodynamic changes due to increased sympathoadrenal activity which could precipitate serious negative effects in compromised patients . The pressor response could be blunted by dexmedetomidine which is a selective alpha 2 agonist which might provide hemodynamic stability during tracheal intubation.

Conditions

  • Pressor Response

Interventions

DRUG

PRECEDEX INJ★ 2ML

this group will receive single dose of dexmedetomidine 0.5 mcg /kg in 50 ml normal saline over 10 min IV infusion

DRUG

PRECEDEX INJ★ 2ML

single dose of dexmedetomidine 1 mcg /kg in 50 ml normal saline over 10 min IV infusion

Sponsors & Collaborators

  • Theodor Bilharz Research Institute

    lead OTHER

Principal Investigators

  • Moshira Sayed Lecturer of anesthesia and intensive care, M.D. · Theodor Bilharz Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2024-05-01
Completion
2024-05-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06592027 on ClinicalTrials.gov